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Genetic Differences in Drug Metabolism
Associated with Ocular Toxicity*
by Hitoshi Shichit and Daniel W. Nebertt
The tissue localization and subcellular distribution of drug-metabolizing enzymes in the eye
are described. With the use of inbred strains of mice, the [Ah] complex is shown to be an
important experimental system for probing genetic differences in drug metabolism and related
drugtoxicities. Although the genetic system described indetail here involves mice, there isample
evidence that the same system operates in man.
Genetic differences in acetaminophen- and naphthalene-induced cataract formation and other
ocular degeneration are shown to be related to the [Ah] complex. Because this toxicity appears
similar to senile cataracts, we propose that certain types of drug-induced cataracts might exist
among clinical populations of senile cataracts but that any cause-and-effect relationship would
be very difficult to determine because of underlying interindividual differences in genetic
predisposition. It is therefore suggested that genetic differences in drug metabolism be an
important consideration in the clinical assessment of ocular toxicity caused by drugs and other
environmental pollutants.
Introduction
Other contributions in this symposium are con-
cerned with drug toxicity and pathology related to
tissues ofthe head and neck. This paper deals more
directlywiththedrug-metabolizingenzymesinvolved.
These enzymes are responsible fortoxification (i.e.,
potentiation of the toxic response by forming a
reactive drugintermediate), as well as detoxication
(metabolism leading to the excretion of innocuous
products). This paper also emphasizes genetic
differences in these enzymes, whereas genetics is
not addressed in the other contributions. Although
the genetic system described in detail here involves
mice, there is ample evidence that the same system
operates in man. It therefore should be obvious
that, due to differences in genetic predisposition
among individuals in the human population, a
particular dose of an ophthalmic drug might be
toxic to one person but not to another (and these
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twopersonsmightevenbe siblings). Similargenetic
differences in toxicity caused by drugs and other
environmental pollutants are expected to be mani-
fest among other tissues of the body, as well as in
the eye.
We first describe the tissue localization and
subcellulardistributionofdrug-metabolizingenzymes
in the eye. Next, the genetic system, called the
[Ah] complex, is introduced. Finally, genetic dif-
ferencesinacetaminophen-andnaphthalene-induced
cataract formation (lens opacification) and other
ocular degeneration are shown to be related to the
[Ah] complex.
Concept of Extrahepatic Drug
Metabolism
Until the last two decades, it was generally
accepted that the liver was the only important
organ for drug metabolism. More recently, howev-
er, it has become clear that virtually every cell of
every plant and animal (and certain bacteria) con-
tains drug-metabolizing capability. At least part of
this appreciation reflects the development of much
moresensitiveassaysfordrug-metabolizingenzymes.
107Toxification and detoxication of drugs and other
environmental pollutants in extrahepatic tissues
therefore can be important (1).
The eye isno exception. Forexample, chloroquine
retinopathy observed in malaria patients was attrib-
uted to an accumulation ofunusually high levels of
chloroquine in the eye (2). Unless the eye possesses
a mechanism for removing such drugs that enter
ocular tissues via the circulating blood, therefore,
accumulated chemicals of all types might exert
adverse effects on photoreceptor cells, leading to
visual impairment. Shortly after Bernstein's report
(2), cytochrome P-450, a principal component ofthe
drug-metabolizing enzyme system,* was detected
spectrally in the pigmented epithelium of bovine
retina (4). Although much progress has been made
in studies on absorption, distribution, and clinical
usefulness of ophthalmic drugs (5), information on
ocular drug metabolism and toxicity remains quite
scanty, in spite of obvious clinical importance.
Futher, information about genetic differences in
ocular drug toxicity is even more scarce. Steroid-
induced glaucoma is a pharmacogenetic disorder,
for example, although the etiology is unknown.
About 5% of the United States population is
homozygous for the recessive allele causing glau-
coma induced by corticosteroid ophthalmic medica-
tions (6).
P-450-Mediated Monooxygenase
Activities and Other Coordinated
Drug-Metabolizing Enzymes
Many environmental pollutants and other foreign
compounds are chemicals that are so hydrophobic
they would remain in the body indefinitely were it
not for the metabolism resulting in more polar
derivatives. These drug-metabolizing enzyme sys-
tems, which are localized principally in the liver,
are usually divided into two groups: phase I and
phase II. During phase I metabolism, one or more
polar groups (such as hydroxyl) are introduced into
the hydrophobic parent molecule, thus allowing a
handle, or position, for the phase II conjugating
enzymes (such as UDP glucuronosyltransferase) to
attack. The conjugated products are sufficiently
*In this paper, cytochrome P-450 is defined as all forms of
CO-binding hemoproteins associated with membrane-bound
NADPH-dependent monooxygenase activities. We define cyto-
chrome P1-450 as all forms of CO-binding hemoprotein that
increase in amount concomitantly with rises in induced AHH
activityfollowingpolycyclic aromatic inducertreatment. In view
of more than one such form of P1450 (3), it is emphasized that
this definition of P1-450 is simplistic.
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polar, so that these detoxified chemicals are now
excreted from the body (7).
One ofthe mostinterestingofthe phase I enzyme
systems is agroup ofenzymes known collectively as
the P-450-mediated monooxygenases (3). These
membrane-bound enzyme systems metabolize poly-
cyclicaromatichydrocarbons suchasbenzo[a]pyrene
(ubiquitous in city smog, cigarette smoke and
characoal-cooked foods) and biphenyl; halogenated
hydrocarbons such as polychlorinated and polybro-
minated biphenyls, insecticides, and ingredients in
soaps and deodorants; strong mutagens such as
N-methyl-N'-nitro-N-acetylarylamines and nitro-
furans; numerous aromatic amines, such as those
found in hair dyes; nitro aromatics and heterocy-
clics; wood terpenes; epoxides; carbamates; alkyl
halides; safrole derivatives; certain fungal toxins
and antibiotics; manyofthe chemotherapeutic agents
used to treat human cancer; most drugs; small
chemicals such as benzene, thiocyanate, or ethanol;
both endogenous and synthetic steroids; and other
endogenous compounds such as biogenic amines,
indoles, thyroxine, and fatty acids.
Evidence is growing that metabolism to reactive
intermediates by cytochrome P-450-mediated mono-
oxygenases is a prerequisite for mutagenesis, car-
cinogenesis, andtoxicitycausedbynumerousdrugs,
polycyclic hydrocarbons, and other environmental
pollutants. The steady-state levels ofthese reactive
electrophilic intermediates and, consequently, the
rates at which they interact with the critical
nucleophilic target, are dependent upon a delicate
balance between their generation and detoxication
(Fig. 1). Changes in the balance between toxifica-
tion and detoxication in any particular tissue of an
individual may therefore affect his risk of tumori-
genesis or toxicity.
Subcellular Localization and
Distribution of Drug-Metabolizing
Enzymes in the Eye
The distribution (Table 1) and subcellular local-
ization (Table 2) ofseveraldrug-metabolizing enzyme
activities were studied in bovine eye. AHH activi-
tyt was chosen as an example of phase I metabo-
lism (reflectingbasalforms ofP-450). UDPglucuro-
nosyltransferase, glutathione transferase, and N-
acetyltransferase activities are typical phase II
enzymes (9). y-Glutamyltranspeptidase and cystine
tAbbreviations used include: AHH, aryl hydrocarbon (ben-
zo[a]pyrene) hydroxylase (EC 1.14.14.1); B6, the C57BL/6N
inbred mouse strain; D2, the DBA/2N inbred mouse strain.
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FIGURE 1. Scheme forthemembrane-bound multicomponent monooxygenase system(s)andthevariouspossiblyimportantpathways
for hydrophobic substrates (8). For any given substrate, the relative balance between metabolic activation and detoxication likely
would differ among different tissues, strains, and species. Age, genetic expression, nutrition, hormone concentration, diurnal
rhythm, pH, saturating versus nonsaturating conditions of the substrate, Km and Vm for each enzyme, subcellular
compartmentalization of each enzyme, efficiency of DNA repair, and the immunological competence of the animal-may all be
important factors affecting this balance.
Table 1. Distribution of AHH, UDP gli
-in various tissues ofbovine
eye.
Enzyme activity, units/mg proteina
Tissues AHH UDP Glucuronosyltransferase y-Glutamyltranspeptidase
Retina 0.03 6 400
Lens Not detectable 5 3
Cornea 0.02 8 320
Iris 0.15 23 640
Pigmented epithelium-choroid 0.31 84 430
Ciliary body 5.74 396 3850
aTissue homogenates were used for assay ofenzymic activities. One unit ofactivityis the amount ofenzyme protein that produces 1
pmole ofproduct per minute. Enzyme activities given here are specific activities, i.e., units/mg of tissue protein/minute.
Table 2. Subcellular activities of enzymes involved in mercapturate synthesis in the bovine eye.a
Glutathione transferaseb -y-Glutamyltranspeptidase Cystine aminopeptidase N-Acetyltransferase
Pigmented Pigmented Pigmented Pigmented
Subcellular Ciliary epithelium- Ciliary epithelium- Ciliary epithelium- Ciliary epithelium-
fraction body choroid body choroid body choroid body choroid
Tissue homogenate 5210 480 3850 430 100 8 13 2
Nuclei 780 230 270 67 1 Not 7 1
detectable
Mitochondria 1400 120 1620 310 73 7 64 2
Microsomes 3690 590 5120 570 1130 54 160 8
Supernatant 6340 870 1230 130 450 13 13 Not
detectable
aActivities are expressed as units/mg protein. See Table 1 for definition of one unit of activity.
bWith 1-chloro-2,4-dinitrobenzene as the substrate.
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FIGURE 2. Retinal and uveal blood circulation systems (dashed
lines). The retinal circulation provides nutrients for the
retinal neurons, while the uveal circulation supplies nutrients
for the pigmented epithelium (and visual cells), the ciliary
body (and lens and cornea), and the iris. Large arrows denote
entry ofnutrients and exit ofmetabolic products between the
uveal circulation (choroidal capillaries) and the pigmented
epithelium. Small arrows indicate aqueous humor secretion
by the ciliary body into the anterior chamber and aqueous
humor.
aminopeptidase are important in the pathway from
glutathione conjugates ofaromatic hydrocarbons to
mercapturate formation (10). Most, if not all, of
these six enzymes (Tables 1 and 2) are induced by
various drugs or other environmental pollutants (3,
9, 10). Low levels of -y-glutamyltranspeptidase (11)
andglutathione transferase (12) have beenreported
in the lens.
We conclude from Tables 1 and 2 that virtually all
ocular tissues have detectable drug-metabolizing
capability (13-15). The ciliary body and pigmented
epithelium-choroid are by far the richest in these
activities (see Fig. 2 forthe location ofthese tissues
in the eye). In fact, the specific activities of AHH
and UDP glucuronosyltransferase in the ciliary
body are only about 10 to 20 times less than those in
bovine liver.
The [Ah] Complex: Genetic
Expression of Induced AHH
Activity and P1-450 Induction
The [Ah] complex is an experimental model
system that has provided several good examples of
a delicate balance between genetic and environ-
mental factors in the etiology of cancer, drug
toxicity and birth defects (16). The [Ah] complex of
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Table 3. Induction ofocular AHH activity in B6 and D2 mice
by polycyclic aromatic compounds.
Specific AHH activity,
units/mg proteina
Intraperitoneal treatment B6 D2
Control 0.08 0.06
3-Naphthofiavone 0.36 0.07
3-Methylcholanthrene 0.39 0.08
2,3,7,8-Tetrachlorodibenzo- 0.47 0.10
p-dioxin
aSee Table 1. Tissue homogenates of the entire eye were
prepared for the enzyme assay.
the mouse regulates the induction (by polycyclic
aromatic compounds such as 3-methylcholanthrene,
benzo[a]pyrene, or 2, 3, 7, 8-tetrachlorodibenzo-p-
dioxin) ofnumerousdrug-metabolizing enzyme "activ-
ities"associated withseveral(ormany)newinduced
forms of cytochrome P1-450. The [Ah] complex
comprises numerous regulatory, structural, and
probably temporal genes that may ormay not be on
the same chromosome.
At any given dose of inducer, the induction of
AHH activity and at least two dozen other mono-
oxygenase activities and associated forms ofP1-450
occursin3-methylcholanthrene-treated B6andother
genetically "responsive" inbred strains andis always
much lower in 3-methylcholanthrene-treated D2
andothergenetically"nonresponsive"strains. Besides
the liver, this genetic expression is seen in such
tissues as lung, kidney, intestine, lymph nodes,
skin, bone marrow, pigmented epithelium of the
retina (Table 3), brain, mammary gland, uterus,
ovary and testis. The genetic response is therefore
called "systemic," oroccurringthroughout virtually
all tissues of the animal. Responsiveness to aro-
matic hydrocarbons has been designated the [Ah]
complex: Ah is the dqminpnt allele; Ah is the
recessive allele; the AhIAh bhetQrozygote is phe-
notypically similar to the Ah lAh mouse in terms
of degree of responsiveness. The trait of Ah-
responsiveness among crosses involving B6 and D2
mice is therefore autosomal dominant (16).
Several studies indicate that the fundamental
genetic difference resides in the Ah regulatory
gene (Fig. 3), which encodes the cytosolic receptor
capable of binding to inducers such as 3-methyl-
cholanthrene, benzo[a]yprene, and 2,3,7,8-tetra-
chlorodibenzo-p-dioxin. To our knowledge, only cer-
tain foreign chemicals bind to this receptor with
saturability and high affinity (less than 1 nmole).
The B6 receptor appears to have at least 50 times
better ?ffinity toward inducers of P1-450 than the
Ah IAh mouse (18). Translocation of the inducer-
Environmental Health PerspectivesFIGURE 3. Diagram ofa cell and the hypothetical scheme by which a cytosolic receptor, product ofthe regulatory Ah gene, binds to
inducer (17). Depending upon the half-life ofthe reactive intermediate, the rate offormation ofthe intermediate, and the rate of
conjugation and other means to detoxify the intermediate-important covalent binding may occur in the same cell in which
metabolism took place, or in some distant cell. Although the "unknown critical target" is illustrated here in the nucleus, there is
presently no experimental evidence demonstrating unequivocally the subcellular location of a "critical target(s)" required for the
initiation ofdrug toxicity or cancer. (Reproduced with permission).
receptor complex into the nucleus has been demon-
strated in the Ah-responsive heterozygote and
homozygote (18) and requires a temperature-
dependent step (19). Discrepancies between the
dextran-charcoal adsorption assay and the sucrose
density gradient assay have been recently under-
stood via chromatographic studies ofthe Ah recep-
tor (20).
What happens in the nucleus is not yet known
(Fig. 3), but somehow the "information" (that these
inducers.of P1-450 exist in the cell's microenviron-
ment) is received; the response is transcription of
specific mRNA's, translation ofthese mRNA's into
specific enzymes such as P1-450, and incorporation
of P1-450 into cellular membranes. These induced
enzymes may aid in detoxication or they may
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generate increased amounts of reactive intermedi-
ates.
The Ah Complex in Human
Populations
In spite of shortcomings with the AHH assay in
human cultured lymphoblasts (8, 21), a growing list
of clinical disorders appears to be associated with
the human [Ah] complex. There clearly exists
sufficient evidence that heritable variation ofAHH
inducibilityoccursinman. Experimentaldifficulties,
however, make it impossible at this time to be
certain whetherAHH inductionis controlled byone
or more genetic loci.
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FIGURE 4. (A, C) Genetically nonresponsive AhdlAhd homozygote, and (B, D) genetically responsive Ak IAh heterozygous sibling
from the B6D2F1 x D2 backeross (23). These photographs were taken 5 hr after the mice had received acetaminophen and 53 hr
after the mice had received 3-methylcholanthrene, an inducer ofP1-450. (E, F) Hematoxylin- and eosin-stained sections of ocular
tissue from mice in (A) and (B), respectively ( x 500). The tissues from top to bottom are iris, cornea and lens. Vacuoles seen in the
subepithelial layer ofthe lens in (F) are the result ofhydration ofthe lens cells and are always associated with cataract formation
(24). Doses ofmore than 1000 mg ofacetaminophen/kg body weight were almost always fatal toAhblAhd mice within the first 8 hr
afteracetaminophen administration, but these doses were notlethal, nor didthey ever cause lens opacification toAhdlAhd mice. At
lower doses ofacetaminophen (400 to 800 mg/kg), the ocular opacity developed more slowly inAhb/Ahd mice. Ifa cataract did not
appearwithin 10 hrafter acetaminophen administration, however, no cataract developed subsequently. The degree ofopacification
that had developed within these 10 hr was never reversible. (Reproduced with permission).
Correlation between the Ahb
Allele and Lens Opacification
Caused by Intraperitoneal
Acetaminophen
Acetaminophen, awidelyusedanalgesic-antipyretic
agent, ismetabolized to atoxic intermediate largely
by some form ofpolycyclic aromatic-induced P1-450
(16). Therefore, we theorized that Ah-responsive
112
mice-following treatmentwithpolycyclicaromatic
inducers to enhance P1-450 levels-would display
moreacetaminophentoxicitythanAh-nonresponsive
mice. This hypothesis turns out to be true not only
inliver, where hepaticnecrosis and covalentbinding
ofacetaminophen metabolites occur (22), but also in
the lens, where cataract formation was found (Fig.
4). Anabsolute correlation isfoubnd (Fig. 5) between
lens opacification and the Ah allele among four
Ah-responsive inbred mouse strains, five Ah-
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FIGURE 5. Correlation between the hepatic AHH inducibility
andcataractogenesis amongfivenonresponsiveinbredstrains
(0), fourdresponsive inbred strains (0), ajnd tie (0)responsive
(Ah lAh) and (0) nonresponsive (Ah lAh ) progeny from
the B6D2F1 x D2 backeross (25). Eachsymbolrepresents an
individual mouse. Allmicehad received 3-methylcholanthrene
intraperitoneally 48 hr prior to intraperitoneal acetamino-
phen. The eyeswere evaluated with anophthalmic slitlamp 5
hr following acetaminophen treatment: a = no signs of
opacification; 1+ = about 50% opacification; 2+ = complete
opacification. The mice were then immediatelykilled, andthe
liver microsomal hydroxylase activity was determined.
nonresponsive inbred strains and amongchildren of
the B6D2F1 x D2 backeross.
Figure 6 illustrates the effects ofacetaminophen
on glutathione concentrations in the liver and lens
of3-methylcholanthrene-pretreated B6and D2mice.
As expected, hepatic glutathione depletion is more
pronounced in B6 than in D2 mice. Quite unexpect-
edly, however, lenticular glutathione levels are not
depleted in either B6 or D2 mice following the large
intraperitoneal dose of acetaminophen.
One possibility is that acetaminophen and its
metabolites do not reach the lens and therefore
glutathione is not depleted. This possibility was
ruled out with the use of radiolabeled acetamino-
phen (Fig. 7). Similar kinetics of covalent binding
occurs in both liver and lens protein, and in each
case B6 tissues exhibit two to five times greater
covalent binding than the corresponding D2 tis-
sues.
Howcancovalent bindingofacetaminophenmetab-
olites occurin the apparent absence ofany glutathi-
one depletion? At least two possible answers come
to mind. First, assuming glutathione depletion in
the lens is necessary for cataract formation, one
might envision some sort of compartmentalization
of glutathione. In other words, although total lens
glutathione concentrations are similar in B6 and D2
mice, asubcellulardepletionofglutathione (directly
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FIGURE 6. Totalglutathione (GSH) levelsin (0,0)theliverand
(A, A) lens of 3-methylcholanthrene-treated B6 mice (@, A)
and D2 mice (o, A) following a large dose (1,000 mg/kg) of
intraperitoneal acetaminophen (25).
in the anterior subcapsular region ofthe lens where
the cataracts develop) might occur in B6 but not in
D2. Such a localized depletion might be augmented
by a sudden influx of reactive intermediates (gen-
erated by the liver, ciliary body or whatever) so
that local concentrations of the toxic agent far
exceed local concentrations of glutathione in and
near the anterior chamber. Alternatively, ocular
toxicity may develop by a mechanism independent
of glutathione levels. Electrophilic reactive inter-
mediates could cause changes in cellular macromol-
ecules in many ways: alterations in oxidations and
reductions of endogenous molecules, free radical
formation, permeability changes in the lens mem-
brane, alterations in metabolism of endogenous
substrates, etc.
Very large doses ofacetaminophen were used for
the experimentsillustrated in Figures4-7. The only
clinical situation that such large doses might be
achieved would be attempted suicide. Relevant
observations, however, have been recently report-
ed. Upon hearing a seminar about the data in this
report, Cohen and Burk (26) examined ten patients
showing evidence of acetaminophen-induced hepa-
totoxicity due to self-inflicted overdoses. The age
range was 17 to 45 years old, with only two women
more than 23 years ofage. One ofthese patients, a
45-year-old alcoholic about whom no previous medi-
cal history was available and who died 1 day later,
was found on admission to have bilateral diffuse
cataracts; no previous history of cataracts was
known. She also was the only fatality in the series
of 10 cases (26).
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.Table 4. Effect of oral acetaminophen or naphthalene on cataract formation in B6 and D2 mice.
Intraperitoneal Drug con- Mean body weightd Incidence
Inbred P1450 inducer Oral centration, cataracts,
strain treatmenta treatmentb mg/mlc Day 0 Day 21 Day 60 % Comments
B6 3-Methyl- Acetamino- 5 15.7 (15) 17.1 (13) (0) 13.3 Two developed bilateral cataracts
cholanthrene phen about day 10 and both died
1 to 2 weeks thereafter
D2 " " 5 14.6 (15) 16.9 (15) (0) 0 No cataracts at time of death
B6 3-Methyl- Acetamino- 10 16.2 (15) 17.6 (12) (0) 13.3 Two developed bilateral cataracts
cholanthrene phen about day 3 and both died
within the next 2 weeks
thereafter
D2
t t 10 15.9 (15) 17.7 (15) (0) 0 No cataracts at time of death
B6 3-Naphtho- Acetamino- 5 16.4 (15) 19.9 (15) 21.5 (15) 6.7 One developed a unilateral
flavone phen cataract about day 14; this was
examined when mouse was
killed 7 months later
D2
it 5 15.4 (15) 20.5 (15) 22.8 (14) 0 No cataracts
B6 P-Naphtho- Acetamino- 10 15.9 (15) 20.8 (14) 22.3 (4) 13.3 One developed a unilateral
flavone phen cataract about day 11 and another
developed bilateral cataracts
about day 14; both died about
day 36
D2 " 10 16.9 (15) 21.6 (14) 23.9 (14) 0 No cataracts
B6 ,-Naphtho- Naphthalene 5 15.4 (15) 19.4 (14) 20.7 (13) 6.7 One developed bilateral cataracts
flavone about day 27; these were
examined when mouse was
killed 6 months later
D2 '
i 5 16.5 (15) 20.3 (15) 21.3 (15) 0 No cataracts
B6 P-Naphtho- Naphthalene 10 15.4 (15) 17.2 (13) 18.8 (12) 6.7 One developed a unilateral
flavone cataract about day 8; this was
examined when mouse was
killed 7 months later
D2
Ft 10 16.5 (15) 16.7 (15) 19.4 (15) 0 No cataracts
aInjections twice weekly (25).
1'The drug was dissolved in corn oil and the food was soaked in this solution of corn oil.
cEstimated drug concentration in corn oil in which the food was soaked.
dMean body weights ofgroup during feeding of the drug. The number of survivors is shown in parentheses.
Effect of Daily Oral
Acetaminophen or Naphthalene
on Cataract Formation
In additional experiments, we chose oral doses of
acetaminophen, lower doses that are used clinically
(Table 4). Oral naphthalene was also chosen for
study because its monooxygenation is also cata-
lyzed b!y some form of P1-450 and associated with
the Ah allele (16). Naphthalene-induced cataracts
have been described (27) in workers from dye and
chemical factories. The cataractogenic agent is
claimed (28) not to be naphthalene itselfbut rather
1,2-naphthoquinone, which is formed from naph-
thalene-1,2-dihydrodiol. This diol of naphthalene
reaches the eye via the bloodstream. Pathways of
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naphthalene metabolism have been extensively inves-
tigated both in vivo (29) and with liver microsomes
in vivo (30-32). The phenol and the reactive arene
oxide ofnaphthalene and acetaminophen are conju-
gated with glucuronide, sulfate, and glutathione.
Relatively small numbers of B6 mice develop
detectable cataracts when acetaminophen or naph-
thalene is ingested daily (Table 4). Phenobarbital
induces these conjugating pathways, and this fact
may explain ourfinding (25) that oral phenobarbital
cancompletelypreventacetaminophen-induced cat-
aract formation. It is possible that the reactive
intermediate ofacetaminophen is an arene oxide or
a quinone. No D2 mouse ever developed aceta-
minophen- or naphthalene-induced cataracts. All
micetreatedwith3-methylcholanthrene diedwithin
6 weeks, apparently due to the cytotoxicity of the
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FIGURE 7. Covalentbindingof[3H]acetaminophen metabolite(s) toliverandlensproteinsof3-methylcholanthrene-treated (0) B6and
(0) D2 mice (25).
chemical when injected twice weekly. On the other
hand, ,-naphthoflavone treatment was not very
toxic; relatively few animals died during 60 days of
daily oral acetaminophen or naphthalene combined
with intraperitoneal P-naphtoflavone twice weekly.
Out ofthe nine B6 mice that developed cataracts on
these various oral regimens, three remained oth-
erwise healthy for 6 or 7 months, at which time the
animals were killed in order to examine histologi-
cally the lenticular opacities.
Histology of Ocular Toxicity
Induced by Oral Acetaminophen
Upon close microscopic examination, we found
that tissue degeneration occurs not only in the
anterior lens cortex but also in large areas of the
uveal tract (Fig. 8a, c). The retina and pigmented
epithelium are normal (Fig. 8b). The degeneration
seen in the choroid, ciliary body and iris appears to
be of a chronic nature. Anterior synechiae and
inflammatory cells at the angle are frequently
observed. The number of epithelial cells is usually
decreased in cataracts that were young (several
hours or several days old). Intermittent loss ofcells
from the lens epithelial layer is seen in cataracts
that had been present for at least 1 week (Fig. 8c).
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The gradual loss ofthe epithelial cells might result
inmetabolicderangementsinthelensfibers, thereby
leading to lens opacification. All lenses from D2
mice similarly treated do not show any evidence of
ocular abnormalities.
Possible Interrelationship among
Genetic Differences in Drug
Metabolism, Drug-induced
Cataracts and Senile Cataracts
in the Human Population
Cataracts induced by chemicals and drugs, espe-
cially naphthalene, have been extensively investi-
gated because oftheir similarity to senile cataracts
(28, 33, 34). The problem oftrying to assess ocular
toxicity in elderly patients receiving large daily
doses ofacetaminophen would be far more difficult
than to study patients attempting suicide with
acetaminophen, becauseofthecombinationofgenetic
factors (i.e., the [Ah] complex in man) and envi-
ronmental factors (i.e., history of cigarette smok-
ing, other drugs prescribed, dietary intake, etc.).
Perhaps there exist other drugs in this same
category: they may cause ocular toxicity in a
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for more than 1 month (25). (a) Light micrograph showing ciliary body, iris and trabecular meshwork. Note the presence of
inflammatory cells in the angle (arrowhead) and the degenerative changes inthe ciliary body. Anatrophic iris and a certainamount
of cellular infiltration of the episclera are observed. A peripheral anterior synechia is also seen. x 200. (b) Light micrograph
showing the retina and choroid. Chronic degeneration of the choroid was frequently seen. The retina shows an almost normal
appearance. x 200. (c) Light micrograph of the anterior cortical zone of the cataractous lens. Note the intermittent loss of
epithelial cells from the epithelial cell layer (arrowheads). x 230.
116 Environmental Health Perspectivesgenetically determined small proportion ofthe total
human population. We do suggest, however, that
the ocular toxicity data shown in this report may be
clinically important to certain patients receiving
either a single large overdose of acetaminophen or
high doses over a long period of time.
The expert secretarial assistance of Ms. Ingrid E. Jordan is
greatly appreciated.
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